Hemogenyx Pharmaceuticals provided an update on its cancer and viral disease treatment activities and progress on Monday, detailing the expansion of clinical trials, and advancements in the CBR platform and the development of mRNA-based delivery systems.
Hemogenyx announced progress in its clinical trial activities by adding a prestigious US medical centre to its list of clinical trial sites for HEMO-CAR-T, its CAR-T cell therapy. This expansion will enhance the scope and expedite the timeline for implementing clinical trials.
In addition, Hemogenyx is seeking to expand HEMO-CAR-T to include paediatric acute myeloid leukaemia (AML) and a subset of paediatric acute lymphoblastic leukaemia patients. If approved, trials will be implemented at the newly established site.
In immunotherapy, the company’s Chimeric Bait Receptor (CBR) platform aims to reprogram innate immune cells, such as macrophages, to combat viral threats and eliminate specific cancer types. Hemogenyx are developing and testing multiple CBR constructs to identify candidates for targeting rare cancers like epithelial ovarian carcinoma.
“We are excited about the progress we are making across our various programs. The addition of a world-renowned medical center to our HEMO-CAR-T clinical trial sites marks a significant step forward in our mission to develop life-saving therapies. Our expansion into pediatric indications for HEMO-CAR-T highlights our commitment to addressing unmet medical needs in both adult and pediatric populations,” said Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals.
“Furthermore, our advancements in the CBR platform and the development of mRNA-based delivery systems for treating airborne viral infections demonstrate our innovative approach to tackling complex diseases. The progress in our CDX bispecific antibody program also underscores our dedication to bringing effective treatments to patients with relapsed or refractory AML and other severe conditions.
“We are diligently pursuing non-dilutive financing options to support these initiatives and remain focused on translating our scientific discoveries into clinical success. We look forward to updating our shareholders and the market as we continue to make strides in our development programs.”
